Navigation Links
Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting
Date:5/1/2008

-- Presentations highlight Palomid 529 as an inhibitor of macular

degeneration, diabetic retinopathy and retinal scaring from retinal

detachment in animal disease models ---

JAMAICA PLAIN, Mass., May 1 /PRNewswire/ -- Paloma Pharmaceuticals, Inc. today announced it has presented two presentations at the 2008 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) describing the activity of Palomid 529 in a series of models of retinal disease notably macular degeneration, diabetic retinopathy and retinal fibrosis.

P529 is a non-steroidal, synthetic, small molecule drug created through computational design, synthetic and medicinal chemistry, the result of three generations of Palomid design work. Palomid's broad activity as an anti-angiogenic and anti-proliferative agent is shown to reside in its ability to target and inhibit the PI3K/Akt/mTOR signal transduction pathway as a TORC1/TORC2 inhibitor.

The first of the two presentations, "Palomid 529, a Non-Steroidal Small Molecule Anti-Angiogenic Agent Inhibits Retinal and Subretinal Neovascularization by Inhibiting the PI3K/Akt/mTOR Pathway", was given as an oral presentation by Dr. David Sherris, President and CEO of Paloma Pharmaceuticals. The second presentation, "Muller Cell Proliferation and Glial Scar Formation Is Reduced Following Experimental Retinal Detachment Using Palomid 529, an Inhibitor of the Akt/mTOR Pathway", was given by the Drs. Geoffrey P. Lewis and Steven. K. Fisher, presented by Dr. Ethan A. Chapin, of the Neuroscience Research Institute, Neuroscience Research Institute, MCD Biology, University of California-Santa Barbara, Santa Barbara, CA.

"Ocular diseases of both retinal and sub-retinal origin, namely diabetic retinopathy and age-related macular degeneration, are a significant problem in our aging population. In order to create a drug to optimally treat such diseases one needs to prevent or inhibit disease pr
'/>"/>

SOURCE Paloma Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Palomar to Unveil New Laser-Assisted Liposuction Platform at the American Society for Laser Medicine & Surgery
2. Palomar Seeks to License Additional Companies to Home-Use Light-Based Hair Removal Technology
3. Palomar to Debut New Technology at the American Academy of Dermatology Annual Meeting
4. Palomar and Gillette Extend Launch Decision on Home-Use Light Based Hair Removal Device and Agree to Negotiate New Terms
5. Palomar Medical Technologies Third Quarter 2007 Financial Results Conference Call and Webcast
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008
7. Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008
8. Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
9. MAP Pharmaceuticals to Present at Upcoming Investor Conferences
10. Agreement Executed for Amneal Pharmaceuticals to Acquire the Assets of Interpharm Holdings
11. Lotus Pharmaceuticals, Inc. Announces Resignation of Director Mel Rothberg

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...wswire/ -- Reportlinker.com announces that a new m...e: ,, Global In Vitro Diagnostics Market Analy...tlinker.com/p0166596/Global-In-Vitro-Diagnostics-M...lobal In Vitro Diagnostics Market Analysis and For..."Global In Vitro Diagnostics (IVD) Market Analysis...
(Date:12/1/2009)...e-USNewswire/ -- The Kerlan Jobe Orthopaedic Clini...reed to pay the United States $3 million to settle...om HealthSouth Corporation, the Justice Department...es allegations that HealthSouth paid kickbacks to ...nations to the Kerlan Jobe Foundation, loan forgiv...
(Date:12/1/2009)...but more easily identified, study finds , ...c resonance imaging test is highly effective at de...called placenta accreta, researchers report. , ... a fetus attaches too deeply to a woman,s uterus. ...f the uterine wall, rupturing blood vessels and pu...
(Date:12/1/2009)...ire-FirstCall/ -- With employee benefit choices be... are providing self-service decision-making tools ...g to a new survey by Watson Wyatt, a leading globa...er these tools believe they lead employees to make...to the survey, 45 percent of companies offered emp...
(Date:12/1/2009)...RNewswire/ -- Edifecs, Inc., the proven leader in ...lutions announced an enhanced release of Edifecs X... HIPAA 5010 migrations. XEngine Translator provide...ws generation of test data and permits two-way tra...us addressing most requirements for organizations ...
Breaking Medicine News(10 mins):Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 2Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 3Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 4Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 5Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 6Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 7Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 8Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 9Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 10Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 11Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 12Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 13Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 14Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 15Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 16Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 17Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 18Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 19Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 20Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 21Health News:Los Angeles' Kerlan Jobe Orthopaedic Clinic Pays $3 Million to Settle Kickback Allegations 2Health News:Serious Pregnancy Complication Detected With MRI 2Health News:Employers Plan to Increase Use of Self-Service Decision-Making Technology For Open Enrollment, Watson Wyatt Survey Finds 2Health News:Employers Plan to Increase Use of Self-Service Decision-Making Technology For Open Enrollment, Watson Wyatt Survey Finds 3Health News:Edifecs Delivers Enhanced HIPAA 4010A1 to 5010 Migration Capabilities for Healthcare Organizations 2Health News:Edifecs Delivers Enhanced HIPAA 4010A1 to 5010 Migration Capabilities for Healthcare Organizations 3
... SOUTH SAN FRANCISCO, Calif., WASHINGTON, Feb.,19 ...agnosis,may benefit from a new program being intro...iders, patient advocates, health benefit insurers ... Nevada and New Hampshire, promotes,physician and ...
... An error in the most recent,edition of the local...Monroe,Hospital callers to an entirely different k...And callers who expected to schedule their next,ap...mber listing in the white pages,featured correct p...
...Inc. (Nasdaq: NUVA ), a medical device company f...tive surgical treatments for the spine, announced ...earnings announcement, which will take place on We...2:30 p.m. PT to discuss the results. The dial-in ...
...e 30 percent less likely than men to receive a cri...e after a stroke, according to a Michigan State Un...ed Feb. 19 in San Diego at the International Strok...a treatment in the mid-1990s, is a potent blood th...
...s Hopkins ACG System for Provider Profiling, Predi...tment , , BIRMINGHAM, Ala., Feb. 19 DST Heal... Medicare risk adjustment software, DSTHS RiskAnal...d Medicaid Services Hierarchical Conditions Catego...
... and Corporations Collaborate to Stop this Epidemi...Carolina, Blue Cross Blue Shield of Massachusetts,... of Pediatrics and American Dietetic Association j...art Association and the William J. Clinton Foundat...
Other Medicine News:Health News:National Coalition for Cancer Survivorship, UCLA, WellPoint, and Genentech Launch Initiative to Provide Coordinated Follow-Up Care for People Surviving Cancer 2Health News:National Coalition for Cancer Survivorship, UCLA, WellPoint, and Genentech Launch Initiative to Provide Coordinated Follow-Up Care for People Surviving Cancer 3Health News:National Coalition for Cancer Survivorship, UCLA, WellPoint, and Genentech Launch Initiative to Provide Coordinated Follow-Up Care for People Surviving Cancer 4Health News:Monroe Hospital: Laughter is Best Medicine for Unwelcome Publicity 2Health News:NuVasive Announces Web Cast and Conference Call of Fourth Quarter 2008 Results 2Health News:NuVasive Announces Web Cast and Conference Call of Fourth Quarter 2008 Results 3Health News:Women less likely to receive critical care after a stroke, MSU researchers find 2Health News:DST Health Solutions Launches New RiskAnalyzer Software to Help Medicare Advantage Plans Manage Risk Adjustment 2Health News:DST Health Solutions Launches New RiskAnalyzer Software to Help Medicare Advantage Plans Manage Risk Adjustment 3Health News:Alliance for a Healthier Generation Expands Efforts to Combat Childhood Obesity with Launch of Landmark Healthcare Initiative 2Health News:Alliance for a Healthier Generation Expands Efforts to Combat Childhood Obesity with Launch of Landmark Healthcare Initiative 3Health News:Alliance for a Healthier Generation Expands Efforts to Combat Childhood Obesity with Launch of Landmark Healthcare Initiative 4Health News:Alliance for a Healthier Generation Expands Efforts to Combat Childhood Obesity with Launch of Landmark Healthcare Initiative 5Health News:Alliance for a Healthier Generation Expands Efforts to Combat Childhood Obesity with Launch of Landmark Healthcare Initiative 6Health News:Alliance for a Healthier Generation Expands Efforts to Combat Childhood Obesity with Launch of Landmark Healthcare Initiative 7
(Date:12/1/2009)... Merck & Co., Inc. today announ...A) has approved ZEGERID OTC(TM) (omeprazole 20 mg/...-counter treatment of frequent heartburn. ZEGERID...-Plough HealthCare Products, Inc., the consumer he...g-Plough and Merck merged on November 3, 2009. ,...
(Date:12/1/2009)...e/ -- Reportlinker.com announces that a new market..., Latin American Pharmaceutical Market Outlook...ecasts and growth opportunities ,, http://w...ceutical-Market-Outlook-To-2014-Policy-environment...s.html ,, The $28.8bn Latin American market ...
(Date:12/1/2009)... -- Reportlinker.com announces that a new market r..., The Future of Oncology Therapeutics - Market Fo... Pipeline and Deals Analysis ,, http://www.re...rapeutics---Market-Forecasts-to-2015-Competitive-B...ml ,, Summary ,, The author has released ...
Breaking Medicine Technology:FDA Approves ZEGERID OTC(TM) for Over-the-Counter Treatment of Frequent Heartburn 2FDA Approves ZEGERID OTC(TM) for Over-the-Counter Treatment of Frequent Heartburn 3FDA Approves ZEGERID OTC(TM) for Over-the-Counter Treatment of Frequent Heartburn 4Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities 2Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities 3Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities 4Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities 5Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities 6Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities 7Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities 8Reportlinker Adds The Future of Oncology Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Reportlinker Adds The Future of Oncology Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Little Company of Mary Proceeds with Plans to Transform Hospital Campus 59199 1Little Company of Mary Proceeds with Plans to Transform Hospital Campus 59199 2Strategic Alliance Between Televisa and Genomma Lab 59195 1Anpath Group Inc Announces Expansion of Its Distributor Network 5362 1Anpath Group Inc Announces Expansion of Its Distributor Network 5362 2Anpath Group Inc Announces Expansion of Its Distributor Network 5362 3
...Pharmacyclics, Inc.,(Nasdaq: PCYC ) today announ...,1 dose-escalation study to evaluate the safety an...elective inhibitor of Bruton,s tyrosine kinase, or...lapsed or refractory B-cell,non-Hodgkin,s lymphoma...r to,be tested in humans, and is Pharmacyclics, fo...
... Pharmaceuticals Corp. ("Raptor" or the "Company")...pointment of Patrice P. Rioux, M.D., Ph.D., as Chi...onsible for the clinical and regulatory advancemen...rams. , , (Logo: http://www.newscom.com/cgi-bi...ical programs include Delayed-Release Cysteamine (...
Other Medicine Technology:Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 2Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 3Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 4Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 5Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer 2Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer 3Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer 4Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer 5
Innova 3100 Water Bath Shaker
55D Double Platform Shaker 11 x 14
Innova 5000 Muti-Tier Shaker
...up to 16 of AutoGen's tube units to prepare 96 sam...te for bacterial cultures and enzyme reactions, su... simplify your DNA extraction process by preparing...lacing our 6-hole tube units directly onto one of ...
Medicine Products: